Join
Live feed
·
PRReleasevia Quantisnow
Sage Therapeutics Inc. logo

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

ByQuantisnow·Wall Street's wire, on your screen.
SAGE· Sage Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SAGE (Sage Therapeutics Inc.) and more on Quantisnow.